Raub Brock Capital Management LP Has $14.12 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Raub Brock Capital Management LP lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 85,779 shares of the company's stock after selling 3,028 shares during the period. Zoetis accounts for 3.2% of Raub Brock Capital Management LP's portfolio, making the stock its 21st largest position. Raub Brock Capital Management LP's holdings in Zoetis were worth $14,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of ZTS. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC bought a new stake in shares of Zoetis in the fourth quarter worth about $30,000. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter worth approximately $44,000. Asset Planning Inc acquired a new stake in shares of Zoetis during the fourth quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Zoetis in the fourth quarter valued at about $59,000. Institutional investors own 92.80% of the company's stock.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.18% of the company's stock.

Zoetis Price Performance

Shares of Zoetis stock traded down $2.75 on Tuesday, reaching $161.63. 2,197,833 shares of the stock were exchanged, compared to its average volume of 2,550,883. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The firm has a market cap of $71.96 billion, a PE ratio of 29.55, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm's 50 day moving average is $159.07 and its 200-day moving average is $163.75.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.38 earnings per share. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. Piper Sandler boosted their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus dropped their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.